Regulators focusing on transgenic animals
Genetically engineered animals are producing a range of therapies for human use, and The New York Times catches up on the action at companies like GTC Biotherapeutics in Massachusetts, Pharmathene and Pharming. Developing drugs in this field has been a slow and laborious task, and the FDA is now developing new guidelines to help govern how animals are used to produce therapies. Questions are also being asked about the ultimate fate of these animals. Should they be sold for food?
- read the article from The New York Times
Related Articles:
Transgenic chickens used to manufacture proteins. Report
GTC inks new transgenics collaboration deal. Report
EMEA rejects GTC's therapy from modified goats. Report
Pharming gets orphan status for transgenic therapy. Report
Be the first to comment
More stories about EMEA proteins Transgenics Pharmathene Genetically Engineered Animals Pharming Orphan Status GTC Biotherapeutics FDA
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
